VIRX — Viracta Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Viracta Therapeutics Initiates Phase 1B/2 Trial In Epstein-Barr Virus-Positive (Ebv+) Solid Tumors
Brief: Salubris Pharma Ditches Plan To Obtain Right In Viracta's Nanatinostat In China
Brief: Viracta Therapeutics Reacquires Exclusive Development And Commercialization Rights For Its All-Oral Combination Therapy In China
Viracta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Viracta Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Viracta Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Viracta Therapeutics Says FDA Cleared IND Application For Trial In EBV+ Solid Tumors
Brief: Viracta Therapeutics Announces Its Addition To The Russell 2000 Index And Other FTSE Russell Indexes
Brief: Viracta Therapeutics Announces The Initiation Of Naval-1, A Global Pivotal Trial For The Treatment Of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
Brief: Viracta Therapeutics Inc Files For Mixed Shelf Of Upto $200 Million
Viracta Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Viracta Therapeutics Reports First Quarter 2021 Financial Results And Provides Clinical And Corporate Updates
Brief: Viracta And XOMA Announce Multi-License Milestone And Royalty Monetization Transaction
Brief: Viracta Therapeutics Says Increased Size Of Board To Nine
Brief: Viracta Therapeutics Reports Closing Of Merger With Sunesis Pharmaceuticals
Brief: Laurence Lytton Reports 8.8% Passive Stake In Sunesis Pharmaceuticals
Brief: Viracta Therapeutics Announces Presentation Of Updated Phase 2 Data At Ash 2020 And Productive Outcome Of Its Recent End Of Phase 2 Meeting With FDA
Brief: Viracta Therapeutics Says Complete Responses Observed Across Multiple Ebv+ Lymphoma Subtypes In Phase 2 Study
U.S. STOCKS ON THE MOVE-Crypto stocks, Kandi Technologies, big banks